On April 21, 2025, Spruce Biosciences, Inc. announced a 55% workforce reduction effective immediately, incurring around $0.9 million in estimated costs, to focus on developing the tralesinidase alfa enzyme replacement therapy for Sanfilippo Syndrome Type B. Additionally, the company will be delisted from Nasdaq on April 29, 2025, due to failure to meet the minimum bid price requirement, with plans to appeal and implement a potential reverse stock split for compliance.